Lessons for a national pharmaceuticals strategy in Canada from Australia and New Zealand-Reference-Cited by-同舟云学术

Lessons for a national pharmaceuticals strategy in Canada from Australia and New Zealand

Published:2007-07 Issue:9 Volume:23 Page:711-718
ISSN:0828-282X
Container-title:Canadian Journal of Cardiology
language:en
Short-container-title:Canadian Journal of Cardiology

Author:

LeLorier Jacques,Rawson Nigel S.B.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference74 articles.

1. Approval process and access to prescription drugs in Canada;Marra;Arthritis Rheum,2006

2. Drug review in Canada: A comparison with Australia, Sweden, the United Kingdom and the United States;Rawson;Drug Inf J,1998

3. Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996–1998;Rawson;Can Med Assoc J,2000

4. Timeliness of review and approval of new drugs in Canada from 1999 through 2001: Is progress being made?;Rawson;Clin Ther,2003

5. Issues in the approval of, access to, and post-marketing follow-up of new drugs in Canada: A personal viewpoint;Rawson;Pharmacoepidemiol Drug Saf,2002

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Public–private partnership alternative for a national pharmacare program in Canada;Journal of Pharmaceutical Policy and Practice;2023-02-06

2. National Pharmacare in Canada: Equality or Equity, Accessibility or Affordability Comment on "Universal Pharmacare in Canada: A Prescription for Equity in Healthcare";International Journal of Health Policy and Management;2020-01-01

3. The impact of China’s national essential medicine system on improving rational drug use in primary health care facilities: an empirical study in four provinces;BMC Health Services Research;2014-10-25